Tiziana Life Sciences ( (TLSA) ) just unveiled an update.
On May 6, 2025, Tiziana Life Sciences announced promising results from an open-label clinical study of nasal foralumab for treating non-active secondary progressive multiple sclerosis (na-SPMS). The study demonstrated that nasal foralumab is safe, induces regulatory immune responses, reduces microglial activation, and stabilizes clinical progression in patients with progression independent of relapse activity. These findings address a major unmet need in MS treatment and highlight a significant advancement for patients with limited options. The company has initiated a Phase 2 clinical trial to further assess efficacy and safety, with results expected by the end of 2025.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company is pioneering the use of intranasal delivery for immunotherapy, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody, currently in clinical development for multiple sclerosis and other neuroinflammatory diseases.
YTD Price Performance: 79.41%
Average Trading Volume: 705,539
Technical Sentiment Signal: Sell
Current Market Cap: $141.6M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.